Crossmark

Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-025-07818-z

Published Online: 2025-09-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nezirevic, Sara

Anders, Carey

Dent, Susan

Bansal, Rani

Yang, Lexie Zidanyue

Erkanli, Alaattin

Moore, Heather
License Information

Text and Data Mining valid from 2025-09-11

Version of Record valid from 2025-09-11
More Information

Article History

Received: 3 June 2025

Accepted: 25 August 2025

First Online: 11 September 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below